Change over period: —
NSE · SAIPARENT
SAIPARENT
-19.6% from the 52-week high · +23.7% above the low
Sai Parenterals Ltd is a pharmaceutical company engaged in the manufacturing of injectable drugs and formulations. The company focuses on sterile products used in hospitals and clinical settings. Its business model revolves around manufacturing and supplying parenteral medicines to domestic and international markets. Revenue is driven by product sales and contract manufacturing. It emphasizes quality compliance and regulatory standards. The company may also produce generic formulations across therapeutic categories. Growth is supported by rising healthcare demand and export opportunities.
The short version. Return on equity was 2.9% in Mar 2026. Promoter holding was 51.16% in Sep 2026, up 0.00 points over 3 quarters.
1 · The price
How has the stock traded?
SAIPARENT trades 19.6% below its 52-week high and 23.7% above its 52-week low.
2 · The business
Is it growing?
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | 195 | 179 | 198 | 96 |
| Net profit | 11 | 8 | 13 | -7 |
| Net margin % | 5.4 | 4.4 | 6.6 | -6.9 |
| EPS (₹) | 2.38 | 1.79 | 2.98 | -1.8050287200606914 |
Annual
| FY2026 | |
|---|---|
| Revenue | 381 |
| Net profit | 14 |
| Net margin % | 3.7 |
| EPS (₹) | 3.23 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 2.9% in Mar 2026; debt to equity is 0.65.
Profitability · 1 years
Returns and margins
| Mar 2026 | |
|---|---|
| Return on equity % | 2.9 |
| Return on capital % | 3.6 |
| EBITDA margin % | 12.1 |
| Net margin % | 3.7 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 3 quarters.
Down 2.88 pts over 3 quarters.
Down 5.02 pts over 3 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|
| Promoter | 51.16 | 51.16 | 51.16 | 0.0 |
| FII | 5.73 | 4.03 | 2.85 | -2.88 |
| DII | 12.86 | 8.53 | 7.84 | -5.02 |
| Public | 30.26 | 36.29 | 38.15 | +7.89 |
Mutual fund holdings · Oct 2026
4 schemes hold this stock
4 the month before.
- Bandhan Healthcare Fund1.14% of NAV
- Bandhan Mid Cap Fund0.12% of NAV
- Motilal Oswal BSE Healthcare ETF0.04% of NAV
- Bandhan BSE Healthcare Index Fund0.04% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for SAIPARENT are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about SAIPARENT
What is the SAIPARENT share price?
SAIPARENT (SAIPARENT) last closed at ₹495.40, down 1.27% on the day. Its 52-week range is ₹405.70 to ₹623.80.
What is the market cap of SAIPARENT?
SAIPARENT has a market capitalisation of about ₹2,216 crore. Its price-to-earnings ratio is 91.6.
How are SAIPARENT's latest results?
Return on equity was 2.9% in Mar 2026. Promoter holding was 51.16% in Sep 2026, up 0.00 points over 3 quarters.
Who owns SAIPARENT?
As of Sep 2026, shareholding was: Promoter 51.16%, FII 2.85%, DII 7.84%, Public 38.15%.
How many mutual funds hold SAIPARENT?
4 mutual fund schemes held SAIPARENT in October 2026. That compares with 4 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.